Phase II trial of monoclonal antibody J591 in combination with low-dose interleukin-2 [aldesleukin] in patients with recurrent prostate cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2007
At a glance
- Drugs Aldesleukin; J 591
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Oct 2005 New trial record.